相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
Roy Fleischmann et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2016)
The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma
Rebecca L. Boddicker et al.
BLOOD (2015)
Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma
Ramona Crescenzo et al.
CANCER CELL (2015)
Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma
Salvia Jain et al.
CLINICAL CANCER RESEARCH (2015)
Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project
Youn H. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108
Paul M. Barr et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
Can Kucuk et al.
NATURE COMMUNICATIONS (2015)
Final Report of a Phase 2 Clinical Trial of Lenalidomide Monotherapy for Patients With T-Cell Lymphoma
Ethan Toumishey et al.
CANCER (2015)
Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis
J. H. Schatz et al.
LEUKEMIA (2015)
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma
Oreofe Odejide et al.
BLOOD (2014)
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes
Edgardo R. Parrilla Castellar et al.
BLOOD (2014)
GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features
Tianjiao Wang et al.
BLOOD (2014)
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Steven M. Horwitz et al.
BLOOD (2014)
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma
Javeed Iqbal et al.
BLOOD (2014)
Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry
Fredrik Ellin et al.
BLOOD (2014)
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma
Bertrand Coiffier et al.
CANCER TREATMENT REVIEWS (2014)
Multicenter Phase II Study of Mogamulizumab ( KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
Michinori Ogura et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas
Jonathan W. Friedberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)
Kristen Ganjoo et al.
LEUKEMIA & LYMPHOMA (2014)
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas
Teresa Palomero et al.
NATURE GENETICS (2014)
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma
Daruka Mahadevan et al.
CANCER (2013)
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial
Franck Morschhauser et al.
EUROPEAN JOURNAL OF CANCER (2013)
Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma
Sonali M. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
Vivien Mak et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
JAK/STAT signaling in hematological malignancies
W. Vainchenker et al.
ONCOGENE (2013)
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas
George Vasmatzis et al.
BLOOD (2012)
Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters
Francois Lemonnier et al.
BLOOD (2012)
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Rob A. Cairns et al.
BLOOD (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
Francesco d'Amore et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Janus Kinase 3-Activating Mutations Identified in Natural Killer/T-cell Lymphoma
Ghee Chong Koo et al.
CANCER DISCOVERY (2012)
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing
Andrew L. Feldman et al.
BLOOD (2011)
Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
Norbert Schmitz et al.
BLOOD (2010)
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95
Audrey Simon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The ITK-SYK Fusion Oncogene Induces a T-Cell Lymphoproliferative Disease in Mice Mimicking Human Disease
Christine Dierks et al.
CANCER RESEARCH (2010)
Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study
Peter Reimer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations
Chuan-Hsiang Huang et al.
SCIENCE (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets
Pier Paolo Piccaluga et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma -: The MD Anderson Cancer Center experience
MP Escalón et al.
CANCER (2005)
The expression of the Aurora-A gene and its significance with tumorgenesis in non-Hodgkin's lymphoma
Y Yakushijin et al.
LEUKEMIA & LYMPHOMA (2004)
Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification
KJ Savage et al.
ANNALS OF ONCOLOGY (2004)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
分享论文
